| 引用本文: | 王慧,高振,林跃家,万妮,陈斌,王燕清,张慧,张星.既往病毒性呼吸道传染疾病研究对抗COVID-19药物研发的启示[J].中国现代应用药学,2020,37(5):513-524. |
| WANG Hui,GAO Zhen,LIN Yuejia,WAN Ni,CHEN Bin,WANG Yanqing,ZHANG Hui,ZHANG Xing.Implications of Previous Studies on Viral Respiratory Infections for Anti-COVID-19 Drug Development[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(5):513-524. |
|
| |
|
|
| 本文已被：浏览 2702次 下载 1294次 |
码上扫一扫！ |
|
|
| 既往病毒性呼吸道传染疾病研究对抗COVID-19药物研发的启示 |
|
王慧1,2, 高振3,4, 林跃家5, 万妮1, 陈斌1, 王燕清1, 张慧5, 张星6
|
|
1.珠海市丽珠微球科技有限公司创新药研究部, 广东珠海 519090;2.浙江大学高分子科学与工程学系, 杭州 310027;3.深圳大学第一附属医院, 深圳市第二人民医院, 深圳 518035;4.中山大学肿瘤防治中心, 华南肿瘤学国家重点实验室, 广州 510060;5.广东省中医院珠海医院, 广东珠海 519015;6.山西医科大学第六医院, 太原 030001
|
|
| 摘要: |
| 新型冠状病毒肺炎（COVID-19）疫情严重威胁人类的健康，并对世界经济造成了巨大损失。COVID-19是急性爆发性疾病，目前尚无靶向治疗特效药或疫苗上市，主要是对症支持治疗。由于时间紧迫，市场急需，这给医药领域的新药研发带来了巨大挑战。针对2019新型冠状病毒（SARS-CoV-2），充分借鉴既往的病毒（如流感病毒、SARS病毒、MERS病毒、埃博拉病毒等）引起的病毒性呼吸道传染疾病的防治理论和经验，快速形成有效的药物研发方案，是医药工业界应对新突发传染病的重要使命和有力抓手。本文综述了SARS-CoV-2与其他既往流行性病毒引起的急性呼吸道传染性疾病的发现、疫情蔓延和防治，剖析了病毒感染的发病机制，总结了既往病毒感染及防治药物的研究进展，以期为COVID-19的药物研发提供思路和启发。 |
| 关键词: 病毒性呼吸道疾病 新型冠状病毒 SARS MERS 新型冠状病毒肺炎(COVID-19) 肺部给药 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.05.001 |
| 分类号:R978.7 |
| 基金项目:国家自然科学基金项目（81802537）；中国博士后科学基金项目（2019M652950）；广东省“珠江人才计划”第六批引进创新创业团队项目（2016ZT06Y229） |
|
| Implications of Previous Studies on Viral Respiratory Infections for Anti-COVID-19 Drug Development |
|
WANG Hui1,2, GAO Zhen3,4, LIN Yuejia5, WAN Ni1, CHEN Bin1, WANG Yanqing1, ZHANG Hui5, ZHANG Xing6
|
|
1.R&D of Innovative Medicine, Zhuhai Livzon Microsphere Technology Co., Ltd., Zhuhai 519090, China;2.Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China;3.The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen 518035, China;4.State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China;5.The Zhuhai Hospital of Guangdong TCM Hospital, Zhuhai 519015, China;6.The Sixth Hospital of Shanxi Medical University, Taiyuan 030001, China
|
| Abstract: |
| The COVID-19 epidemic seriously threatened human health and caused huge losses to the world economy. COVID-19 is an acute explosive disease. Currently, symptomatic treatment is the only option for the patients who are suffering from COVID-19 and there is very few targeted medications or vaccines available in the market. Due to the lack of time and the urgent need for the market, which brings great challenges to the research and development of new drug in the pharmaceutical field. Therefore, seeking therapeutic options for treatments of COVID-19 based on previous theories and experience such as influenza virus, SARS-CoV, MERS-CoV, Ebola virus etc. Which caused viral respiratory infectious diseases is a critical priority. This review summarizes progresses of pharmacotherapeutic options and detection, spread and preventions of SARS-CoV-2 and other types of viruses that could cause epidemic pneumonia, and discusses the mechanism of virus infection, aiming to provide broad ideas and perspectives for developing novel medications against COVID-19. |
| Key words: viral respiratory infectious diseases SARS-CoV-2 SARS MERS COVID-19 pulmonary drug delivery |
|
|
|
|
